Ascendis Pharma A/S (ASND) FinancialsASNDAscendis Pharma A/S

Ascendis Pharma A/S (ASND) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial sale of products, accounting for 92.8% of total sales, equivalent to €314.91M. Other significant revenue streams include Milestones and Sale of clinical supply. Understanding this composition is critical for investors evaluating how ASND navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Ascendis Pharma A/S maintains a gross margin of 91.85%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 64.98%, while the net margin is 61.00%. These profitability ratios, combined with a Return on Equity (ROE) of 118.78%, provide a clear picture of how effectively ASND converts its operational activities into shareholder value.

In the context of the broader market, ASND competes directly with industry leaders such as JAZZ and HCM. With a market capitalization of $16.30B, it holds a leading position in the sector. When comparing efficiency, ASND's gross margin of 91.85% stands against JAZZ's 76.30% and HCM's 45.32%. Such benchmarking helps identify whether Ascendis Pharma A/S is trading at a premium or discount relative to its financial performance.

Ascendis Pharma has shown remarkable financial recovery, with a net income of €629.34 million in Q1 2026 and €206.97 million in Q2 2026, compared to significant losses in previous quarters. The gross margin remains strong at 91.85% in Q2 2026, indicating effective cost management and profitability potential.